Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19087063 | 1.00 | HSD11B1 (0.46) | HSD11B1KDM5AKCNH2CHRM2CHRM4 | |
| SCHEMBL10274489 | 0.90 | KCNH2 (0.52) | HSD11B1KDM5AKCNH2CHRM1SPR | |
| SCHEMBL29352448 | 0.89 | DRD4 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL171599 | 0.89 | DRD4 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16488067 | 0.85 | ALDH1A1 (0.44) | HSD11B1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3845634 | 0.80 | DRD4 (0.50) | HSD11B1DRD4DRD2PDCD1LG2CD274 | |
| SCHEMBL19117549 | 0.80 | DRD4 (0.50) | HSD11B1DRD4DRD2PDCD1LG2CD274 | |
| SCHEMBL15025142 | 0.79 | HSD11B1 (0.49) | HSD11B1KDM5ACHRM2CHRM4CHRM5 | |
| SCHEMBL2076700 | 0.79 | HSD11B1 (0.46) | HSD11B1KDM5ACHRM2CHRM4CHRM5 | |
| SCHEMBL2737376 | 0.79 | KDM5A (0.48) | HSD11B1KDM5ACHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | claimed |
| WO-2024081345-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2023239710-A1 | BENZOPYRIMIDIN-4(3H)-ONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3804535-A1 | SHISHA STONE | VitaSalts AG (LI) | 2021-04-14 | — | — | EP | disclosed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1874731-A4 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-7402579-B2 | Quinobenzoxazine analogs and compositions | CYLENE PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1874731-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7253290-B2 | 3-[2,2-dimethyl-3-oxo-3-(7-azabicyclo[2.2.1]heptan-7-yl)propoxy]-4-[(1S)-1-methyl-2-[(isopropoxycarbonyl)imino(-3-pyridin-4-yl-pyrrolidin-1-yl)methyl]aminoethyl]-5-(3,5-dimethylphenyl)-1H-pyrazole; prodrugs for treating prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenoma | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006113509-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYP2W1, NQO2, UGT2B7 | HSD11B1 612/4885KDM5A 683/4885KCNH2 1039/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | HSD11B1 3042/4885KDM5A 1154/4885KCNH2 2940/4885 |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYP2W1, NQO2, UGT2B7 | HSD11B1 612/4885KDM5A 683/4885KCNH2 1039/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | HSD11B1 2164/4885KDM5A 218/4885KCNH2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.